A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Navitoclax in Combination With Ruxolitinib Versus Best Available Therapy in Subjects With Relapsed/Refractory Myelofibrosis (TRANSFORM-2)

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 22 Jul 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Navitoclax (Primary) ; Ruxolitinib (Primary) ; Danazol; Fedratinib; Hydroxycarbamide; Peginterferon alfa-2a
Indications Essential thrombocythaemia; Myelofibrosis; Polycythaemia vera
Focus Registrational; Therapeutic Use
Acronyms TRANSFORM-2
Sponsors AbbVie; AbbVie Germany

Most Recent Events

16 Jul 2024 This trial has been Discontinued in Bulgaria, according to European Clinical Trials Database record.
15 Jul 2024 Planned primary completion date changed from 7 Nov 2024 to 29 Jan 2025.
13 Jul 2024 This trial has been Discontinued in Sweden, according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight